IGC Pharma’s Short‑Term Rally Masks Deep Structural Weaknesses
IGC Pharma’s brief 4.2% rise masks deep cash‑burn and fierce competition in the cannabinoid‑therapeutics niche—investors need to weigh high risk before buying.
3 minutes to read
IGC PHARMA INC
IGC Pharma Slides to 52‑Week Low as Market Volatility Hits Cannabinoid Biotech
IGC Pharma slides to a 52‑week low amid liquidity and valuation concerns; investors weigh cannabinoid‑based pipeline risk and potential upside.
3 minutes to read